Select therapeutic use:

Arthritis/rheumatic disorders:

Indications for TALTZ:

Active psoriatic arthritis. Active ankylosing spondylitis. Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

Adult:

Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj sites. ≥18yrs: Psoriatic arthritis: 160mg (two 80mg injs) at Week 0, then 80mg every 4 weeks; may be given alone or in combination with a conventional DMARD. With coexistent plaque psoriasis: 160mg (two 80mg injs) at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks. Ankylosing spondylitis: 160mg (two 80mg injs) at Week 0, then 80mg every 4 weeks. nr-axSpA: 80mg every 4 weeks.

Children:

<18yrs: not established.

Warnings/Precautions:

Increased risk of infections. If a serious infection develops, monitor closely and discontinue until resolves. Evaluate for TB infection and treat latent TB prior to initiating; monitor for active TB during and after therapy. Active TB infection: do not start. History of latent or active TB without confirmed adequate course of treatment: consider anti-TB therapy prior to initiation. Monitor for inflammatory bowel disease; discontinue and treat if occurs. Discontinue immediately and treat if a serious hypersensitivity reaction occurs. Complete all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-17A antagonist.

Interactions:

Avoid concomitant live vaccines. Monitor CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); consider dose adjustment of these substrates.

Adverse Reactions:

Inj site reactions, upper respiratory tract infections, nausea, tinea infections.

Generic Availability:

NO

How Supplied:

Single-use prefilled autoinjector—1, 2, 3; Single-use prefilled syringe—1

Pricing for TALTZ

1 autoinjector of 80mg/ml carton (Qty: 1)
Appx. price $5644
GoodRx

Psoriasis:

Indications for TALTZ:

Moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.

Adult:

Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj sites. ≥18yrs: 160mg (two 80mg injs) at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks.

Children:

<6yrs: not established. Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj sites. ≥6yrs (<25kg): initially 40mg (0.5mL) at Week 0, then 20mg (0.25mL) every 4 weeks; (25–50kg): initially 80mg at Week 0, then 40mg every 4 weeks; (>50kg): initially 160mg (two 80mg injs) at Week 0, then 80mg every 4 weeks.

Warnings/Precautions:

Increased risk of infections. If a serious infection develops, monitor closely and discontinue until resolves. Evaluate for TB infection and treat latent TB prior to initiating; monitor for active TB during and after therapy. Active TB infection: do not start. History of latent or active TB without confirmed adequate course of treatment: consider anti-TB therapy prior to initiation. Monitor for inflammatory bowel disease; discontinue and treat if occurs. Discontinue immediately and treat if a serious hypersensitivity reaction occurs. Complete all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-17A antagonist.

Interactions:

Avoid concomitant live vaccines. Monitor CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); consider dose adjustment of these substrates.

Adverse Reactions:

Inj site reactions, upper respiratory tract infections, nausea, tinea infections.

Generic Availability:

NO

How Supplied:

Single-use prefilled autoinjector—1, 2, 3; Single-use prefilled syringe—1

Pricing for TALTZ

1 autoinjector of 80mg/ml carton (Qty: 1)
Appx. price $5644
GoodRx